Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (ISRCTN11926317) titled 'A study of JNJ-78278343 in combination with JNJ-95298177 for treatment of prostate cancer' on Aug. 15.
Study Type: Interventional
Study Design:
Interventional non randomized (Safety, Efficacy)
Primary Sponsor: Janssen-Cilag International NV
Condition:
Prostate cancer
Cancer
Prostatic neoplasms
Intervention:
The study will be conducted in 2 Parts:
Part 1: Dose Confirmation Participants will receive JNJ-78278343 (Pasritamig) in combination
with JNJ-95298177 (ARX517) in a dose de-escalation schedule in accordance with the Bayesian Optimal Interval
Design (BOIN) design to determine the recommended phase 2 co...